Treating psychotic disorders in their earliest stages has become a key focus
for research and clinical care. This paper reviews evidence of the capacity
to identify those at increased risk for psychotic disorder and to intervene
in the identified, high-risk individuals to ameliorate the course of
disorder. Issues involved in preventive oriented clinical care are
addressed, such as risk/benefit considerations, ethical and safety issues
and the value of stage-specific interventions. Clinical predictors
identified in recent research, promising intervention trials and proposed
clinical practice guidelines are described. An approach based on active
engagement, support and monitoring, yet with a conservative approach to
medication use is advocated at present. Potential neurobiological processes
have been studied and reinforce the sense that this is a critical phase for
active treatment, and may prove helpful in understanding the process of
transition across stages of illness. More research is required in
prediction, neurobiology and treatment